As MEK inhibition becomes more common for patients with NF-1, serial molecular analyses of patient samples will be critical to unravel mechanisms of treatment response and optimize molecular therapies for NF-1-associated peripheral nervous tumors and NF-1-associated central nervous system tumors, such as gliomas. The gene discussed is MAP2K7; the disease is central nervous system cancer.